Alto Neuroscience’s P-IIb Trial of ALTO-100 for Major Depressive Disorder Couldn’t Achieve its Primary Endpoint
Shots:
- The P-IIb trial assessed ALTO-100 vs PBO among adults (n=301) with major depressive disorder (MDD) using a memory-based cognitive biomarker across the US. Results did not align with the P-IIa data
- Study couldn’t depict significant improvement in depressive symptoms among the biomarker-defined MDD group & did not meet 2EPs; safety profile was favorable without any new concerns. The company plans to analyze the full data to determine future steps for ALTO-100 in MDD
- ALTO-100 is being studied in a P-IIb trial as an adj. for bipolar depression. In addition, the company’s current cash is expected to support operations through 2027, incl. two additional MDD readouts for ALTO-203 & ALTO-300 anticipated in H1’25
Ref: Alto Neuroscience | Image: Alto Neuroscience
Related News:- Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWeek 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
